Steven Disanti, DO
General Practice · Genoa, ILNPI 1578582474
Payments from drug & device makers
Across 785 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Sunovion Pharmaceuticals Inc.$1K
- Lilly USA, LLC$1K
- Novo Nordisk$958
- plus $9K from 37 others
What the payments were for
- Food & beverage$20,09399%
- Education$1391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,231 in reported general payments places this provider in the 95th percentile of 3,816 general practice providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 445 | $168,499 |
| JardianceEmpagliflozin | 243 | $145,472 |
| XareltoRivaroxaban | 198 | $81,983 |
| IngrezzaValbenazine Tosylate | 16 | $64,196 |
| TrulicityDulaglutide | 57 | $63,554 |
| JanuviaSitagliptin Phosphate | 77 | $48,086 |
| AptiomEslicarbazepine Acetate | 60 | $37,944 |
| MounjaroTirzepatide | 17 | $31,385 |
| Risperdal ConstaRisperidone Microspheres | 18 | $24,401 |
| FarxigaDapagliflozin Propanediol | 38 | $20,381 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,111 |
| OzempicSemaglutide | 13 | $13,300 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $11,724 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 186 | $11,613 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 112 | $11,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $496 | $168,499445 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $2,209 | $151,047255 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $2,929 | $106,384216 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,212 | $94,94074 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $856 | $64,19616 claims |
| MerckJanuvia, Steglatro | $664 | $53,06992 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,246 | $37,94460 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $151 | $36,05857 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,707 | $31,46449 claims |
| Novo NordiskOzempic | $958 | $13,30013 claims |
| AbbVieLinzess, Lumigan | $190 | $11,61028 claims |
| NovartisEntresto | $333 | $8,42127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,816 general practice providers in Illinois.
Other general practice in Genoa
- Ryan MolisBurr Ridge$13M
- Ronald StumbrisPalos Heights$3.8M
- Lou GrahamChicago$603K
- Kenya ThomasChicago$595K
- Brijesh PatelSchaumburg$547K
- Alan BoghosianChicago$349K
- Anthony PonzioElmwood Park$253K
- Dennis HartliebGlenview$160K
- Miguel NayanWestmont$149K
- Peter HarnoisHinsdale$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.